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1. Introduction
The routine indication of endomyocardial biopsy (EMB) in myocarditis has long been a matter
of debate [1]. Although always claimed as the ultimate diagnostic tool for myocarditis, its low
sensitivity, low availability, high cost, and the inherent risks of an invasive procedure have
led many physicians to avoid performing it. Yet, at present EMB continues to be the “gold
standard” for the diagnosis of myocarditis [2].
Since its introduction in the early 1960s by Sakakibara and Konno many improvements have
been made in the technique and some progress has been made in the analysis of the samples.
The introduction of the Dallas Criteria [3] in 1986 was the first effort to make histological
diagnosis more consistent, but still they have a very low sensitivity and lack prognostic value
in many clinical studies [4-7].
After the Dallas criteria, the use of immunohistochemistry to better identify mononuclear cells
infiltrating myocardial tissue added significant sensitivity to histological diagnosis [8, 9]. Also,
introduction of polymerase chain reaction (PCR) applied to isolation of viral genomes from
EMB samples became a promising tool. Both proved to carry prognostic value in some studies,
but results have been not consistent in all publications.
Moreover, development of noninvasive methods to assess myocardial injury in myocarditis,
particularly magnetic resonance image (MRI), provides a very interesting alternative to EMB,
although some authors suggest that they may be complementary [10].
© 2013 González et al.; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
In this chapter we will review the most relevant evidence of the clinical usefulness of EMB and
all these developing techniques.
2. Technical issues on endomyocardial biopsies
The first approach to obtain tissue samples from the heart was proposed in the 1950s by Vim
and Silverman by using a needle introduced through a limited thoracotomy. The high
incidence of pneumothorax and cardiac tamponade made this technique not accepted [11]. It
was in 1962 that for the first time Sakakibara and Konno reported their technique of EMB
introducing the bioptome in order to sample the endocardium [12]. After developmentof the
bioptome, many improvements have been made in terms of flexibility and maneuverability,
making the procedure safer and easier.
The possibility of peripheral vein access made the right ventricle the most attractive site for
sampling, especially the interventricular septum because it is thicker than the right ventricular
free wall and it is located in the natural path of blood flow [11]. Anyway, if needed, the left
ventricle may be reached through the femoral artery and across the aortic valve [13].
According to current recommendations of the International Society of Heart and Lung
Transplantation [14] and the American Heart Association, American College of Cardiology
and European Society of Cardiology [2] a minimum of 4 -5 samples of 1 – 2 mm3 in size should
be collected at room temperature to prevent contraction band artifacts. Additional samples
may be taken if special procedures are required as immunohistochemistry (IHC), transmission
electron microscopy, and/or polymerase chain reaction.
Complications of EMB have been prospectively studied by Decker et al. [15] in 546 consecutive
procedures. The overall complications rate was 6%, 2.7% related to sheath insertion and 3.3%
related to the biopsy procedure itself. Perforation was observed in only 3 patients (0.5%) with
2 deaths attributable to perforations (0.3%). The detailed report is summarized in table 1.
Related to Sheath Insertion = 15 (2.7%)
Arterial puncture during local anesthesia = 12 (2%)
Vasovagal reaction = 2 (0.4%)
Prolonged venous oozing after sheath removal = 1 (0.2%)
Biopsy Procedure = 18 (3.3%)
Arrhythmias = 6 (1.1%)
Conduction abnormalities = 5 (1%)
Pain without perforation = 4 (0.7%)
Perforation = 3(0.5%), 2 patients died (0.3%)
Table 1. Complications of EMB (Deckers et al. [15])
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3. Current recommendations for the use of endomyocardial biopsies
In an attempt to better determine the clinical use of EMB, a committee of experts from the
American Heart Association, the American College of Cardiologists and the European Society
of Cardiology developed a consensus statement about when EMB was to be used in 14 clinical
scenarios [2]. It is remarkable that in only 2 of those scenarios the recommendation reaches
recommendation level I. Table 2 summarizes the 14 clinical situations, the level of recommen‐
dation, and evidence for the use and clinical value of EBM.
Nº Clinical Scenario EMB usefulness Level of
recom.
Level of
evid.
1 New-onset heart failure of <2 weeks’
duration associated with a normal-size
or dilated left ventricle and
hemodynamic compromise
Distinguish between lymphocytic
myocarditis (good prognosis) and GCM or
NEM that require immunosupressant
treatment.
I B
2 New-onset heart failure of 2 weeks’ to 3
months’ duration associated with
dilated left ventricle and new-onset
ventricular arrhythmias, second- or
third-degree heart block, or failure to
respond to usual care within 1 to 2
weeks
Distinguish between lymphocytic
myocarditis (good prognosis) and GCM
that requires immunosupressant
treatment.
I B
3 Heart failure of >3 months’ duration
associated with dilated left ventricle
and new-onset ventricular arrhythmias,
second- or third-degree heart block, or
failure to respond to usual care within 1
to 2 weeks
Cardiac sarcoidosis is a special differential
diagnosis in this setting. Sarcoidosis
responds very well to corticosteroid
treatment. GCM is also a possibility in this
scenario.
IIa C
4 Heart failure associated with a DCM of
any duration associated with suspected
allergic reaction and/or eosinophilia
Detect HSM and stop offending
medication and start high dose
corticosteroids.
IIa C
5 Heart failure associated with suspected
anthracycline cardiomyopathy
Although anthracycline toxicity can be
detected by means of noninvasive test,
EMB has better sensitivity to detect earlier
stages and stop offending drug earlier.
Requires TEM.
IIa C
6 Heart failure associated with
unexplained restrictive cardiomyopathy
Although a great progress has been made
in the use of noninvasive tests such as
CMR in the assessment of restrictive
IIa C
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Nº Clinical Scenario EMB usefulness Level of
recom.
Level of
evid.
cardiomyopathy, EMB still remains the
only diagnostic tool for many of them.
7 Suspected cardiac tumors When diagnosis is not possible through
other methods. Not recommended in
typical myxoma because of embolization
risk.
IIa C
8 Unexplained cardiomyopathy in
children
Differential diagnosis IIa C
9 New-onset heart failure of 2 weeks’ to 3
months’ duration associated with a
dilated left ventricle, without new-onset
ventricular arrhythmias or second- or
third-degree heart block, that responds
to usual care within 1 to 2 weeks
Seldom GCM can be diagnosed in this
setting. EMB should not be performed
routinely.
IIb B
10 Heart failure of >3 months’ duration
associated with a dilated left ventricle,
without new ventricular arrhythmias or
second- or third-degree heart block,
that responds to usual care within 1 to
2 weeks
In recent trials patients showing
enhanced expression of HLA molecules in
EMB had some benefit from
immunosuppressant therapy.
Hemochromatosis may be a differential
diagnosis in this setting.
IIb C
11 Heart failure associated with
unexplained HCM
Some entities, specially infiltrating
diseases that can thicken heart walls, can
be diagnosed with EMB (Pompe’s and
Fabry’s diseases, amyloidosis).
IIb C
12 Suspected ARVD/C Rarely needed because CMR generally
establishes the diagnosis.
IIb C
13 Unexplained ventricular arrhythmias Generally shows myocarditis or
nonspecific findings.
IIb C
14 Unexplained atrial fibrillation Not recommended III C
CRM, Cardiac Magnetic Resonance; DCM, Dilated Cardiomyopathy; GCM, Giant Cell Myocarditis; HSM, Hypersensitivity
Myocarditis; NEM, Necrotizing Eosinophilic Myocarditis; TEM, Transmission Electron Microscopy.
Table 2. Clinical Recommendations for the Use of EMB [2].
4. The anatomopathological picture of different types of myocarditis
We will briefly describe the pathological features of the main pathologies cited in this chapter
that constitute the differential diagnosis of lymphocytic myocarditis:
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• Lymphocytic myocarditis
• Giant cell myocarditis
• Sarcoidosis
• Hypersensitivity myocarditis
• Eosinophilic myocarditis
4.1. Lymphocytic myocarditis
The pathological picture of lymphocytic myocarditis is the infiltration of myocardium by
activated T lymphocytes, with or without signs of myocyte injury, as illustrated by the EMB
sample of a patient with cytomegalovirus (CMV) myocarditis shown in figures 1-3. Figure 3
also shows the characteristic nuclear inclusions of CMV infection. Histological findings are
generally diffuse but may be focal in nature (figure 4) making multiple samples and immu‐
nohistochemistry necessary for greater diagnostic accuracy.
Figure 1. Myocarditis. Endomyocardial biopsy demonstrating a diffuse infiltration of lymphocytes. H-E. 40 X.
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Figure 2. Myocarditis. Biopsy sample of the case illustrated in Figure 1. A dense infiltrate of lymphocytes and myocyte
necrosis isevident. H-E- 100X.
Figure 3. Myocarditis. Biopsy sample of the case illustrated in Figures 1 and 2. Lymphocytic myocarditis by cytomega‐
lovirus infection. Note the characteristic “owl’s eye” nuclear inclusions (arrows). H-E. 400X
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Figure 4. Focal myocarditis. Inflammation is quite focal. Note necrotic myocytes infiltrated by lymphocytes (circle) H-E
200X.
In order to better standardize histological diagnosis, Dallas criteria have been developed (table
3), for first and subsequent biopsies. Active myocarditis is defined as the presence of lym‐
phocytes infiltrating myocardium plus evidence of myocyte injury (excluding contraction
bands, a common artifact in EMB samples). Borderline myocarditis is defined as milder
infiltrates without evidence of myocyte injury.
For subsequent biopsies, ongoing myocarditis, resolving (healing) myocarditis (figure 5) and
resolved (healed) myocarditis categories have been created if infiltrates are the same as first
biopsy, less than the first biopsy or have disappeared respectively.
First biopsy
Active myocarditis, with or without fibrosis
Borderline myocarditis
No myocarditis
Subsequent biopsy
Ongoing (persistent) myocarditis, with or without fibrosis
Healing (resolving) myocarditis, with or without fibrosis
Healed (resolved) myocarditis, with or without fibrosis
Table 3. Dallas criteria for the diagnosis of myocarditis
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Figure 5. Healing myocarditis. Diffuse lymphocytic infiltrate is mingled with interstitial fibrosis. Note the scattered
atrophic myocytes. H-E 200X.
4.2. Giant Cell Myocarditis (GCM)
This specific form of myocarditis of unknown cause is particularly aggressive with a high
mortality. Extensive myocyte necrosis with an intensive infiltrate of lymphocytes, plasma cells
and eosinophils are seen. The most striking characteristic, which names the disease, is the
presence of giant multinucleated cells in the borders of necrotic areas (figure 6). Multinucleated
cells are originated from macrophages. The most abundant cells in the remaining infiltrates
are CD8+ T-lymphocytes. The main differential diagnosis of GCM is sarcoidosis, which is
differentiated for:
• Eosinophils are abundant in GCM and absent in sarcoidosis
• Fibrotic scarring is more prominent in sarcoidosis
• No granulomas are seen un GCM
• Sarcoidosis may affectepicardium, never affected by GCM
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Figure 6. Giant cell myocarditis. A dense infiltrate of lymphocytes with prominent giant cells isobserved. Note the ab‐
sence of well-established granulomas. H-E 200X.
4.3. Sarcoidosis
Sarcoidosis is a systemic disease that may affect the myocardium. The presence of granulomas
on EMBs may reach 20% of cases. The compromise is patchy and EMBs may be negative. Non-
caseificating granulomas consisting of histiocytes, giant cells, lymphocytes and plasma cells
are the most prominent feature of the disease. Focal infiltrates of lymphocytes are seen, but
they lack eosinophils seen in GCM. Patchy fibrosis is also a frequent finding (figure 7).
Figure 7. Sarcoidosis. Endomyocardial biopsy demonstrates a well-established, non-necrotizing granuloma. Giant cells
are evident. H-E 200X.
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4.4. Hypersensitivity myocarditis
Although not very common, hypersensitivity to drugs may involve the myocardium. The
suspicion of this entity should arise when a patient presents with acute heart failure in the
context of a hypersensitivity reaction to a drug. Tissue samples show a chronic perivascular
infiltrates with lymphocytes, macrophages and plasma cells, with a prominence of eosinophils.
Myocyte injury may be seen but is not a prominent feature. Fibrosis is absent.
4.5. Eosinophilic myocarditis
Myocarditis may be present up to in 25% of patients with hypereosinophilic syndrome.
Extensive infiltration with eosinophils is present in this type of myocarditis (figure 8) but two
distinctive features help distinguishing it from hypersensitivity myocarditis: the presence of
myocyte necrosis and the presence of intracavitary thrombi containing eosinophils, which can
also be seen in the lumen of intramyocardial coronary vessels.
Figure 8. Hypereosinophilia. The interstitial infiltrate is suggestive of hypersensitivity myocarditis. H-E 200X
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5. The role of endomyocardial biopsy in the management of myocarditis
Endomyocardial biopsy is still considered the “gold standard” for diagnosis of viral myocar‐
ditis. The use of Dallas criteria, although questioned, remains almost universal. The develop‐
ment of IHC and PCR for processing EMB samples widened its usefulness.
5.1. The rise, decline and validity of the Dallas criteria
The Dallas criteria for histopathological diagnosis of myocarditis were introduced in 1986 [3]
in the intent of standardizing the way in which EMB would be analyzed and became, since
then, a “gold standard” for the definitive diagnosis of myocarditis.
As previously stated, active myocarditis was defined as the presence of inflammatory
infiltrates associated with myocardial injury not characteristic of ischemic heart disease, and
borderline myocarditis was defined as a les intensive infiltrate without evidence of myocyte
damage.
Furthermore, most clinical investigation on myocarditis have used the Dallas criteria as the
main inclusion criteria [16]. The main weakness of Dallas criteria is low sensitivity (about 25%)
to detect infiltrates in myocardial samples, mainly due to: 1) the patchy nature of myocardial
infiltrates makes sampling error a great concern, 2) the lack of consistent interpretation of EMB
samples, even among most experienced pathologists.
The issue of sampling error has been addressed by many authors. Chow and Hauck published
on postmortem EMB showing that one sample had a sensibility of 25% to detect myocarditis,
and that 5 samples were needed to raise this figure to 66% [17, 18]. Similar experience has been
published with the use of EMB to detect allograft rejection [19, 20].
On the other hand, the lack of interobserver agreement in the interpretation of histological
samples shows that that the Dallas criteria did not achieve completely their goal. It is remarka‐
ble that of the 111 patients enrolled in the Myocarditis Treatment Trial (positive EMB accord‐
ing to Dallas criteria required as inclusion condition) only 64% had the diagnosis confirmed by
the expert pathologist panel [21]. In another study where 7 expert pathologists examined the
EMB of 16 patients with dilated cardiomyopathy (DCM), interpretation of samples varied re‐
markably. Diagnosis of myocarditis was made in 11 patients at least by 1 pathologist. But only
in 3 patients, three pathologists agreed in the diagnosis, and in 5, two pathologists agreed,
showing that even for expert pathologists, interpretation of EMB is quite variable [22].
Some investigators showed that many patients with a clinical presentation suggestive of
myocarditis were negative for Dallas criteria but had a PCR positive for viral genomes in the
EMB. Martin el al. studied 34 children with clinical presentation suggestive of myocarditis.
Twenty-six of the 34 samples were positive for viral genomes but only 13 of the 26 were positive
for Dallas criteria [23]. Pauschinger et al. found that 24 of 94 patients with idiopathic dilated
cardiomyopathy (DCM), all of them negative for Dallas criteria, were positive for viral
genomes [24]. In another study, Pauschinger et al. demonstrated positive PCR for enterovi‐
ruses in 45 patients with idiopathic DCM; only 6 were positive for Dallas criteria [25]. Why et
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al. showed in 120 patients with DCM that 41 were positive for enterovirus genomes in their
EMB, but only 5 were positive for Dallas criteria [26].
Dallas criteria also lack prognostic value. Grogan et al. compared the clinical outcome in 27
patients with myocarditis and 58 patients with idiopathic DMC; presence of myocarditis did
not affect prognosis [4]. Angelini et al. followed 42 patients with biopsy proven myocarditis,
26 with active myocarditis and 16 with borderline myocarditis also according to Dallas criteria.
Heart failure was more frequent in the borderline myocarditis (BM) group than in the acute
myocarditis (AM) group. They concluded that myocyte necrosis does not carry prognostic
value [5]. Caforio et al. studied 174 patients, with active myocarditis (n=85) or borderline
myocarditis (n=89). They concluded that IHC enhanced EMB sensitivity for the diagnosis of
myocarditis and that Dallas criteria lacked prognostic value [6]. Kindermann et al. followed
181 patients with clinically suspected myocarditis in whom EMB was performed. Dallas
criteria were positive only in 69 patients (38%), but sensitivity was increased bythe use of IHC,
which showed inflammation in 91 patients. Dallas criteria also proved of no prognostic value
in that study [7].
Moreover, Dallas criteria did not show predictive value to select patients for immunosup‐
pressant therapy. Clinical trials using immunosuppressant treatment for myocarditis did not
show, in general, a better outcome in patients who received treatment compared to those who
received placebo, even though, some patients improved markedly their left ventricular
function after treatment. Dallas criteria did not predict which patients were to improve [21, 27].
The need of new criteria to make the definite diagnosis has been claimed for many authors,
but as shown in the papers cited, the Dallas criteria supported by immunohistochemistry
remain, at present the “gold standard” for the diagnosis of myocarditis.
5.2. The role of immunohistochemistry
The main problem with the histopathological diagnosis of myocarditis in routine samples is
the differentiation between interstitial lymphocytes and other types of cells, mainly fibroblasts
and histiocytes.
Schnitt et al. published a pioneer work in 50 consecutive EMBs assessed by two independent
observers [28].The use of an immunoperoxidase technique to stain specifically leucocyte
common antigen (CLA, now CD45A) had a better interobserver concordance (r=0.83) than
hematoxylin – eosin (H&E) samples (r=0.63) in identifying lymphocytes. Intraobserver
concordance between IHC and H&E-identified lymphocytes was poor (r=0.28 and r=0.14
respectively). The main drawback of CLA antibodies is that it also stains mast cells and
histiocytes. They did not study the impact of the technique in the diagnosis of myocarditis [28].
One of us (JM) emphasized in a pioneer paper in 1990, the need of immunohistochemical stain‐
ing of lymphocytes for the reliable diagnosis of myocarditis in EMB. The diagnosis of myocar‐
ditis was established in 27 patients according to routine staining of EMB samples. We analyzed
those samples using antibodies to CLA, κ and λ immunoglobulin light chains and T cell recep‐
tor (TCR). Only 14 out of the 27 biopsies showed to have true myocarditis [8]. The technique
proved to be useful for diagnosis of myocarditis as a cause of sudden death (figure 9) [30].
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Figure 9. Diffuse myocarditis in a 6 year-old boy found underwater in a swimming pool. There are extensive myocar‐
dial injury and marked interstitial edema and apposition of T- lymphocytes to the sarcolemma of necrotic myocytes.
Immunoperoxidase for T- lymphocytes. Note the classic picnotic nuclei and cytoplasmic positivity (arrows) X200 [30].
After these papers, new markers and new antibodies have been developed and IHC diagnosis
has become more sophisticated. Kühl et al. studied the biopsies of 170 patients with DCM with
no history of previous viral disease. EMB were performed and processed for H&E to determine
the presence of myocarditis according to Dallas criteria, and for immunohistochemistry using
antibodies to CD45RA, CD2, CD3, CD4, CD8, CD45R0 and HLA class I. Only 5% of samples
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were positive for Dallas criteria, but 48% showed positive staining for one or more of the
antibodies, showing a very higher sensitivity of immunohistochemistry to show inflammatory
changes in DCM [29].
Feeley et al. showed that antibodies anti CD45R0 were very accurate for the diagnosis of
myocardial inflammation in a series of 163 routine autopsies in a general hospital. The only 5
samples that showed more than 14 CD45R0 positive cells per high power field belonged to
transplanted patients, of whom three with cardiac rejection and one with a linfoproliferative
disorder [30]. Although not designed to study myocarditis, Krous et al. showed that staining
with anti CD3 (T lymphocytes) and CD68 (macrophages) was useful to differentiate myocar‐
ditis from sudden infant death syndrome and suffocation in EMB of children [31]. And as
previously reported, in our hands immunohistochemical staining allowed the diagnosis of
unapparent myocarditis as a cause of sudden death in children [32].
In a paper by Caforio et al. immunohistochemistry has been used to reinforce Dallas criteria.
More than half of borderline myocarditis diagnosis would have been missed with H&E alone
[6]. In this connection, also Kindermann et al showed in their study that only 69 (38%) out of
181 EMB samples were positive for Dallas criteria while 91 (50%) were positive using CD3,
CD68 and HLA class II antibodies [7].
5.3. The role of polymerase chain reaction
In the early 1990s many authors published series of cases showing the isolation of different
viral genomes with PCR [33-37], but these papers were mainly descriptive of the presence of
certain types of viruses in EMB samples and did not assess prognostic or therapeutic value of
these findings. However, almost a decade after PCR also proved to be of prognostic value [36].
Frustaci et al. treated 41 patients with biopsy proven myocarditis who presented with ongoing
heart failure with complete standard immunosuppressant treatment. Viral genomes were
present in biopsy specimens of 17 non responders (85%), including enterovirus (n=5), Epstein-
Barr virus (n=5) adenovirus (n=4), both adenovirus and enterovirus (n=1), influenza A virus
(n=1), parvovirus-B19 (n=1), and in 3 responders, who were all positive for hepatitis C virus.
Cardiac autoantibodies were present in 19 responders (90%) and in none of the nonresponders.
The presence of viral genomes was independently associated with failure of immunosuppres‐
sion to improve ventricular function [38]. Conversely, Camargo et al. demonstrated that
children with chronic myocarditis have a favorable response to immunosupressant therapy
independently of the presence or not of viral genomes in EMB [39].
Kytö et al. showed in a retrospective analysis of autopsies of 40 fatal myocarditis that viral
nucleic acids were found in the hearts of 17 patients (43%), including CMV (15 patients),
parvovirus B19 (4 patients), enterovirus (1 patient), and human herpes virus 6 (1 patient). In 4
patients, CMV DNA was found in addition to parvovirus B19 or enterovirus genomes. No
adenoviruses, rhinoviruses, or influenza viruses were detected in that study of fatal myocar‐
ditis. In 67% of the patients in whom PCR was positive for CMV, in situ hybridization revealed
viral DNA in cardiomyocytes. Only 1 of these patients was immunocompromised. From these
findings it can be concluded that the finding of CMV genome in EMB biopsies of patients with
myocarditis carries a particularly bad prognosis [40].
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Wilmot et al. also demonstrated the prognostic value of PCR in fulminant myocarditis in
16 children treated with mechanical circulatory support. PCR results were available from
15 patients and were positive in 11. Viral presence was associated with death or need for
transplantation (P = 0.011). Upon histological analysis, absence of viral infection and lack
of myocardial inflammation were associated with recovery (P values 0.011 and 0.044, re‐
spectively) [41].
Mavrogeni et al. followed a cohort of 85 patients with myocarditis. In 71 patients CRM was
positive and in 50 EMB was performed. Chlamydia, herpes virus and parvovirus B19 were
present in 80 % of EMB samples. In 7 patients with clinical deterioration 1 year after, EMB
showed persistence of infectious agent genomes [42].
Viral myocarditis is a known cause of sudden death. In this connection, PCR has been
performed in post-mortem samples of patients with sudden death. The test proved to be of
diagnostic usefulness in some cases [43, 44].
6. Endomyocardial biopsy as a research tool
The role of EMB as a research tool cannot be undervalued. Almost all papers cited in this
chapter have been conducted on EMB samples. Many developments relative to heart disease
are due to basic science investigations using EMB. In this regard, many advances in the
understanding of genetic expression in the failing heart have been made thanks to the
possibility of obtaining heart muscle samples [45-48].
In the specific field of myocarditis, EMB will surely allow to identify better predictors of
mortality, need of transplantation and response to certain drugs or therapeutic strategies
by  the  discover  of  new molecular  markers  of  inflammation,  tissue  damage  or  survival.
With PCR the prognostic value of viral genome presence will be better defined promptly
and,  in the future,  the expression of  certain myocyte genes will  surely introduce a new
tool to predict outcomes.
7. Conclusions
As shown by the data revised here, EMB is an important diagnostic tool in myocarditis. It
still remains the gold standard for the definite diagnosis. Dallas criteria, although severe‐
ly questioned by many authors, still remain a reference method to establish diagnosis and
are generally required as inclusion criteria in clinical investigation. On the other hand, it
helps distinguishing lymphocytic myocarditis from other entities, like giant cell myocardi‐
tis,  necrotizing eosinophilic  myocarditis  or  sarcoidosis,  which may guide  treatment  and
prognosis.
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The introduction of IHC and PCR provided new tools for evaluating EMB samples. Although
not yet standardized adequately, they have shown to give valuable prognostic and therapeutic
information. They have become routine testing in myocarditis.
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